Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
21 Nov 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/jazz-pharmaceuticals-receives-fda-approval-biliary-tract-cancer-treatment-2024-11-21/
19 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-citis-2024-global-healthcare-conference-302310546.html
06 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-302297903.html
31 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-new-data-at-psych-congress-2024-confirming-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-benefits-in-narcolepsy-and-idiopathic-hypersomnia-302293081.html
23 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-third-quarter-financial-results-on-november-6-2024-302284892.html
16 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-statistically-significant-overall-survival-and-progression-free-survival-results-for-zepzelca-lurbinectedin-and-atezolizumab-combination-in-first-line-maintenance-therapy-for-extensive-stage-small-302275803.html
Details:
Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) is being investigated as a maintenance treatment for adults with extensive-stage small cell lung cancer.
Lead Product(s): Lurbinectedin,Atezolizumab
Therapeutic Area: Oncology Brand Name: Zepzelca
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Lurbinectedin,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jazz Pharma’s Zepzelca® Combo Shows Survival Benefit in Lung Cancer
Details : Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) is being investigated as a maintenance treatment for adults with extensive-stage small cell lung cancer.
Brand Name : Zepzelca
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
Epidiolex (cannabidiol) is an oral CB1 receptor NAM. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Brand Name: Epidiolex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jazz Pharmaceuticals Updates Phase 3 Trial of Cannabidiol for Epilepsies in Japan
Details : Epidiolex (cannabidiol) is an oral CB1 receptor NAM. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Brand Name : Epidiolex
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2024
Details:
Epidiolex (cannabidiol) is an oral CB1 receptor NAM, approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Brand Name: Epidiolex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jazz Pharma Updates Phase 3 Cannabidiol Trial For Epilepsy in Japan
Details : Epidiolex (cannabidiol) is an oral CB1 receptor NAM, approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Brand Name : Epidiolex
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2024
Details:
JZP385 (suvecaltamide) is an investigational, highly selective and state-dependent modulator of T-type calcium channels, being evaluated in adult patients with moderate to severe essential tremor.
Lead Product(s): Suvecaltamide
Therapeutic Area: Neurology Brand Name: JZP385
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2024
Lead Product(s) : Suvecaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial for TGCT Treatment
Details : JZP385 (suvecaltamide) is an investigational, highly selective and state-dependent modulator of T-type calcium channels, being evaluated in adult patients with moderate to severe essential tremor.
Brand Name : JZP385
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Details:
JZP598 (zanidatamab) is an investigational bispecific antibody that acts as inhibitor of HER2. It is being evaluated for the treatment of HER2-positive metastatic biliary tract cancer.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Brand Name: JZP598
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Details : JZP598 (zanidatamab) is an investigational bispecific antibody that acts as inhibitor of HER2. It is being evaluated for the treatment of HER2-positive metastatic biliary tract cancer.
Brand Name : JZP598
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 30, 2024
Details:
JZP598 (zanidatamab) is an investigational bispecific antibody that binds two non-overlapping HER2 epitopes, evaluated for HER2-positive metastatic biliary tract cancer treatment.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Brand Name: JZP598
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Jazz Completes BLA for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer
Details : JZP598 (zanidatamab) is an investigational bispecific antibody that binds two non-overlapping HER2 epitopes, evaluated for HER2-positive metastatic biliary tract cancer treatment.
Brand Name : JZP598
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 02, 2024
Details:
Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: Redx Pharma
Deal Size: $880.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Redx Pharma
Deal Size : $880.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Enters Agreement with Redx to Acquire KRAS Inhibitor Program
Details : Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $10.0 million
February 07, 2024
Details:
JZP150 is an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of adult patients with post-traumatic stress disorder.
Lead Product(s): JZP150
Therapeutic Area: Psychiatry/Psychology Brand Name: JZP150
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Lead Product(s) : JZP150
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JZP150 is an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of adult patients with post-traumatic stress disorder.
Brand Name : JZP150
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Details:
Epidiolex (cannabidiol) is an oral CB receptor CB1 receptor negative allosteric modulator. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Brand Name: Epidiolex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jazz Pharmaceuticals Receives Health Canada Approval for Epidiolex® (Cannabidiol Oral Solution) f...
Details : Epidiolex (cannabidiol) is an oral CB receptor CB1 receptor negative allosteric modulator. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Brand Name : Epidiolex
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2023
Details:
The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Small molecule
Recipient: Autifony Therapeutics
Deal Size: $770.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Autifony Therapeutics
Deal Size : $770.0 million
Deal Type : Licensing Agreement
Details : The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2023
ABOUT THIS PAGE
Jazz Pharmaceuticals is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Cannabidiol bulk offered by Jazz Pharmaceuticals
LOOKING FOR A SUPPLIER?